WO2026136613 - METHODS OF TREATING OPHTHALMIC CONDITIONS IN A DEFINED PATIENT POPULATION
National phase entry is expected:
Publication Number
WO/2026/136613
Publication Date
25.06.2026
International Application No.
PCT/US2025/060231
International Filing Date
18.12.2025
Title **
[English]
METHODS OF TREATING OPHTHALMIC CONDITIONS IN A DEFINED PATIENT POPULATION
[French]
MÉTHODES DE TRAITEMENT DE CONDITIONS OPHTALMIQUES DANS UNE POPULATION DE PATIENTS DÉFINIE
Applicants **
ALMON THERAPEUTICS, INC.
Inventors
MURPHY, Randall
FEDEROFF, Howard
Priority Data
63/736,061
19.12.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
|
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2188 | |
| EPO | Filing, Examination, Granting | 12487 | |
| Japan | Filing, Examination, Granting | 2372 | |
| South Korea | Filing, Examination, Granting | 2340 | |
| USA | Filing, Examination, Granting | 4930 |
Total:
24,317
Contact Us
Abstract[English]
The present invention relates to methods for treating an ophthalmic condition in a defined patient in need of treatment thereof. The methods comprise inducing the activity of peroxisome proliferator–activated receptor gamma coactivator-1 alpha (PGC1α) in a defined patient that needs treatment of an ophthalmic condition. The defined patient in these methods has been previously identified as having reduced carboxylesterase 1 (CES1) activity, compared to normal activity levels of CES1.[French]
La présente invention concerne des méthodes de traitement d'une condition ophtalmique chez un patient défini ayant besoin d'un tel traitement. Les méthodes comprennent l'induction de l'activité du coactivateur-1 alpha du récepteur gamma activé par les proliférateurs de peroxysomes (PGC1α) chez un patient défini nécessitant un traitement d'une condition ophtalmique. Le patient défini dans ces méthodes a été préalablement identifié comme présentant une activité réduite de la carboxylestérase 1 (CES1), par rapport aux niveaux d'activité normaux de la CES1.